Welcome to our dedicated page for Marker Therapeutics news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeutics stock.
Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company focused on the development and commercialization of innovative T cell-based immunotherapies and peptide-based vaccines. Specializing in treating both hematological malignancies and solid tumor indications, Marker Therapeutics employs its proprietary MultiTAA T cell technology to cultivate non-engineered, tumor-specific T cells. These T cells target tumor-associated antigens (TAAs) to effectively eliminate cancer cells.
The company’s promising pipeline includes advanced T cell vaccine candidates currently undergoing clinical trials for ovarian and breast cancers. Marker Therapeutics' therapies aim to stimulate both killer and helper T cells, enhancing the immune response in up to 80% of patients. The company's off-the-shelf products are designed for easy integration with other immunotherapeutics, such as checkpoint inhibitors, either as standalone treatments or part of combination regimens.
Marker Therapeutics is actively pursuing multiple clinical trials, including Phase Ib/IIa and Phase II studies, with some programs benefiting from FDA fast track and orphan disease designation. The company's innovative approach aims to overcome the limitations of earlier cancer vaccine technologies, positioning it as a key player in the immuno-oncology space.
In addition to its T cell therapies, Marker Therapeutics is developing peptide-based immunotherapeutic vaccines for metastatic solid tumors and other difficult-to-treat cancers. One of its most notable programs is PolyStart, which seeks to harness and amplify the body's immune response to cancer.
Recent updates from Marker Therapeutics highlight significant advancements in its clinical programs. For example, a study participant with Non-Hodgkin’s Lymphoma, who relapsed after anti-CD19 CAR T cell therapy, tolerated an initial dose of MT-601 well and has remained in complete response for six months.
Marker Therapeutics also reported third-quarter financial highlights and upcoming milestones for its key programs, MT-401 (Acute Myeloid Leukemia) and MT-601 (Lymphoma and Pancreatic Cancer).
Marker Therapeutics, Inc. (Nasdaq:MRKR) reports completion of patient enrollment in its Phase 2 AML trial for lead product MT-401, with a topline readout anticipated in Q2 2022. The company has developed a new nine-day manufacturing process for T cell therapies, increasing potency and reducing production time. Additionally, plans are in place to file INDs for lymphoma and pancreatic cancer by the end of 2022. However, in 2021, Marker reported a net loss of $41.9 million and increased R&D expenses of $27.8 million, compared to $18.9 million in 2020.
Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology firm, announced that CFO Anthony H. Kim will present at two investor conferences in March 2022. The first is the ROTH Annual Conference on March 14 at 11:00 a.m. ET, followed by the Oppenheimer Virtual Annual Healthcare Conference on March 17 at 10:40 a.m. ET. Webcasts of both presentations will be available on the company's website. Marker is focused on developing non-engineered, tumor-specific T cell therapies for hematological malignancies and solid tumors.
Marker Therapeutics (MRKR) reported positive outcomes from the safety lead-in stage of its Phase 2 AML trial, with no severe adverse effects and one MRD positive patient achieving MRD negativity after treatment with MT-401. The company has developed a new T cell manufacturing process, reducing production time to nine days and enhancing product potency and specificity. Plans include expanding their pipeline into solid tumors like pancreatic cancer, with additional IND filings expected by year-end 2022. A conference call will be held today to discuss these developments further.
Marker Therapeutics, Inc. (Nasdaq:MRKR) announced a conference call and webcast on February 16, 2022, at 5:00 p.m. EST to discuss updates on its clinical programs and pipeline. The event will be accessible via the Investors section of the company's website. Marker specializes in next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, focusing on non-engineered, tumor-specific T cells. The company believes its therapies are easier to manufacture and less toxic than current CAR-T and TCR approaches, potentially providing significant clinical benefits.
Marker Therapeutics (NASDAQ:MRKR) announced that the FDA has granted Orphan Drug designation to MT-601, a T cell product targeting pancreatic cancer. The designation highlights MT-601’s potential to treat a disease with a low 5-year survival rate. The product targets multiple tumor-associated antigens and is in a Phase 1 trial showing promising results. The company plans to initiate a multicenter study combining MT-601 with chemotherapy and file an Investigational New Drug Application in 2022. Orphan designation may provide various benefits, including market exclusivity.
Marker Therapeutics (NASDAQ: MRKR) has appointed Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of leadership in clinical development, notably at GlaxoSmithKline. This strategic move is expected to enhance Marker’s capabilities as it develops novel T cell therapies for cancer treatment. Dr. Knobil currently serves as Chief Medical Officer at Agilent Technologies and holds prior roles at Kaleido Biosciences. Her expertise may contribute significantly as Marker Therapeutics advances its immunotherapy initiatives.
Marker Therapeutics (NASDAQ: MRKR) announced that data from its Phase 1 study on MultiTAA-specific T cells will be presented at the 2021 ASH Annual Meeting, set for December 11-14 in Atlanta and virtually. The oral presentation, titled "Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL," will occur on December 12 at 12:30 p.m. ET. The study, conducted in partnership with Baylor College of Medicine, showcases Marker's innovative approach to T cell-based immunotherapies for hematological malignancies.
Marker Therapeutics, Inc. (Nasdaq:MRKR) provided a corporate update and reported Q3 2021 financial results. They continue to advance the Phase 2 trial of MT-401 for post-transplant AML, with first patients dosed and plans to enroll 20 patients by Q4 2021. The company’s cGMP manufacturing facility is operational, supporting ongoing operations and potential future trials. Financially, Marker had cash reserves of $48.7 million, enough to fund operations into Q1 2023. However, the net loss for Q3 2021 was $12.4 million, up from $7.4 million in Q3 2020.
Marker Therapeutics, Inc. (NASDAQ: MRKR), a leader in clinical-stage immuno-oncology, will present at three virtual investor conferences this September. The conferences include the H.C. Wainwright Annual Global Investment Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Presentations will feature key executives, including CFO Anthony H. Kim and CMO Mythili Koneru. Webcasts will be available on the company’s website.
Marker Therapeutics, Inc. (Nasdaq: MRKR) has received a $13.1 million Product Development Research award from the Cancer Prevention and Research Institute of Texas (CPRIT) to support its Phase 2 clinical trial of MT-401, specifically for patients with acute myeloid leukemia (AML) post-hematopoietic stem cell transplant. The trial's focus is on evaluating relapse-free survival in patients treated with MT-401 versus a control group. This funding underscores CPRIT's commitment to advancing cancer research, having awarded over $2.9 billion to Texas institutions since its inception.
FAQ
What is the current stock price of Marker Therapeutics (MRKR)?
What is the market cap of Marker Therapeutics (MRKR)?
What is Marker Therapeutics, Inc.?
What is MultiTAA T cell technology?
What types of cancer is Marker Therapeutics focusing on?
What are the recent achievements of Marker Therapeutics?
How does Marker Therapeutics enhance the immune response in patients?
What is the significance of FDA fast track and orphan disease designation?
What is the PolyStart program?
How does Marker Therapeutics collaborate with other companies?
What are the financial highlights of Marker Therapeutics?
Where can I receive future press releases from Marker Therapeutics?
